Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 123,566

Document Document Title
WO/2017/038767A1
The purpose of the present invention is to provide: a transdermally absorptive composition having improved basic drug skin penetration properties; and a transdermal absorption accelerator for a basic drug. The purpose can be achieved by ...  
WO/2017/038768A1
The purpose of the present invention is to provide a patch preparation which uses a basic drug acid addition salt as a raw material and which has excellent skin permeability of the drug. This patch preparation is formed by providing an a...  
WO/2017/037670A1
Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods ...  
WO/2017/040301A1
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g.,...  
WO/2017/037081A1
The present invention relates to new compounds of formula (1) wherein R is -C(=O)CH2OH or -CH(OH)CH2OH; R1, is =O or OH; R2 is H or OH; R3 is H or C1-C4alkyl; R4 is H or C1C4alkyl. These compounds are obtained by a process using at least...  
WO/2017/034420A1
Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, ...  
WO/2017/035224A1
Highly efficient methods for synthesis of levomethadone hydrochloride or dextromethadone hydrochloride are provided starting from D-alanine, or L-alanine, respectively, with retention of configuration. Methods for treating a subject are ...  
WO/2017/034872A1
The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of d...  
WO/2017/033963A1
The present invention addresses the problem of providing a substance that has an effect of increasing ATP in cells, in particular, an ATP increasing agent that has an effect much stronger than the increasing effect achieved by using inos...  
WO/2017/034418A1
The present invention provides acoustically activated liposome compositions for use as drug delivery vehicles, and to methods for drug release and drug delivery for therapeutic applications.  
WO/2017/033208A3
The invention discloses naltrexone implantable tablets which are devoid of metal salts and corticosteroids, and which provide consistent and controlled amount of naltrexone for 3 months or more; also disclosed is methods of treatment com...  
WO/2017/032874A1
The present invention provides a chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to the neuroexcitatory amino acid glutamate and presents an advantageously high brain exposure upon ora...  
WO/2017/034027A1
The present invention provides an adhesive patch that is capable of exhibiting excellent tackiness when adhered to the skin and reduces peeling from the skin once adhered thereto. This adhesive patch is characterized by including: a supp...  
WO/2017/033966A1
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, R1, R2a, R2b, R3, R4, R5, R9a, R9b, R10, R11, X, Y and Z are as defined in the description.)  
WO/2017/033093A1
Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of tre...  
WO/2017/033019A1
There is provided compounds of formula I, (I) wherein R1, R2, R3 R4, R5, R6, R7a and R7b have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the...  
WO/2017/033946A1
The present invention provides a heterocyclic compound which has an HDAC inhibitory effect and is useful for treating inflammatory diseases and the like, and a medicine containing the heterocyclic compound. The present invention pertains...  
WO/2017/035472A1
Provided are pharmaceutical formulations that include an amyloid polypeptide including at least one D-amino acid, and a pharmaceutically acceptable carrier. Also provided are kits that include the pharmaceutical formulations. Methods tha...  
WO/2017/033951A1
Provided is a novel analgesic. This analgesic is obtained by including an interleukin-31 agonist as an active ingredient.  
WO/2017/030968A1
One of the aspects of the invention is directed toward a method of treating or preventing acute brain or nerve injury in a subject, comprising administering an effective amount of posiphen, or a pharmaceutically acceptable salt of posiph...  
WO/2017/030171A1
[Problem] To provide a compound which has a positive allosteric modulating effect (PAM effect) for an α7 nicotinic acetylcholine receptor (α7 nACh receptor). [Solution] The inventors have achieved the present invention by making studie...  
WO/2017/027967A1
The present application relates to a-substituted amino acid compounds of the Formula (I), compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or ass...  
WO/2017/031330A1
The present disclosure provides methods of reducing protein misfolding and/or aggregation in a cell. The present disclosure provides methods of treating diseases and disorders associated with protein misfolding and/or aggregation.  
WO/2017/029353A1
The invention relates to methods for treating agitation,aggression, apathy and/or anxiety in dementia patients with moderate and severe disease comprising administering a scyllo-inositol compound, in particular scyllo-inositol,or a pharm...  
WO/2017/030167A1
Provided is an agent that is effective, inter alia, for improving memory and cognitive function. The agent is composed of: at least one component (A) selected from naringenin, eriodictyol, 5,7-dihydroxychromone, caffeic acid, protocatech...  
WO/2017/028732A1
Disclosed are a preparation method of an orexin receptor antagonist compound 5-3, crystalline forms I-IV of the compound and preparation method thereof, and application of the crystalline forms in preparation of a drug treating a disease...  
WO/2017/031213A1
The invention generally relates to cyclic compounds and, more particularly, to a compound represented by Structural Formula I: or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the multicyclic compo...  
WO/2017/031276A1
Provided are methods for treating a neurodegenerative disease, such as multiple sclerosis, in a subject who does not present with active lesions (e.g., gadolinium-enhancing lesions), comprising administering an estrogen receptor β ligan...  
WO/2017/031325A1
The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, co...  
WO/2017/030115A1
The present invention provides a compound that has inhibiting activity against mPGES-1 and is useful in the prevention or treatment of pain, rheumatoid arthritis, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arterioscl...  
WO/2017/029820A1
The present invention relates to: a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof; or a radioactive medicine comprising the compound or the salt.  
WO/2017/031427A1
Compounds having activity as mTOR inhibitors are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, and A are as defined here...  
WO/2017/031319A1
Aspects of the disclosure relate to methods for treating disorders using agents for promoting hypoglossal motoneuron excitability. In some instances the disorders include obstructive sleep apnea (OSA), cataplexy, attention deficit/hypera...  
WO/2017/028708A1
The present invention discloses a recombinant lipoprotein modified by monosialotetrahexosylganglioside, an application in preparing a drug carrier thereof, and an application in preparing a drug treating or preventing a disease associate...  
WO/2017/029567A1
A Transdermal Drug Delivery System (TDDS) of the reservoir or plaster type for administrating clobazam for the treatment of various types of anxiety and epilepsy, for 1 day, 2 day, 3 day, 4 day, 5 day, 6 day and/or 7- day continuous appl...  
WO/2017/030973A1
Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distrib...  
WO/2017/025565A1
Compounds of the Formula (I) are provided which compounds are inhibitors of BACE1.  
WO/2017/027345A1
The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.  
WO/2017/025491A1
The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres...  
WO/2017/027136A3
The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaemp...  
WO/2017/027685A3
The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifica...  
WO/2017/025868A1
A compound of Formula (I) is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula (I) as TD02 inhibitors. The invention also relates to the ...  
WO/2017/025532A1
The present invention is directed to the combined use of BACE1 inhibitor of Formula (I) and a compound useful in active or passive Tau immunotherapy, a compound useful in active or passive Aβ peptide immunotherapy, an NMDA receptor anta...  
WO/2017/027848A1
Glycosylated peptides with giycosylation at or near the C-terminal domain of the peptide have an enhanced ability to cross the blood brain barrier (BBB) and/or enhanced half-lives. These glycosylated peptides may be used as drugs. For ex...  
WO/2017/025058A1
Provided are substituted indole compounds and their using methods and uses. In particular, disclosed are indole compounds for 5-hydroxytryptamine reuptake inhibition and/or 5-HT1A receptor agonists, and their pharmaceutical compositions....  
WO/2017/026516A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or a solvate of these. The present invention provides a compound having Nrf2 activation ability.  
WO/2017/025695A1
The invention concerns the compounds of formula (l) in which W, X, Y, Z and Het are as defined in the description. The compounds of formula (I) are modulators of the NURR1 receptor.  
WO/2017/025912A1
The present invention discloses compositions of liquid and gel formulation containing aripiprazole in the form of a patch for transdermal delivery wherein the aripiprazole is present in the amount of 7% w/v, the gel contains a gelling ag...  
WO/2017/025559A1
The present invention provides compounds of Formula (I) for the treatment of neurodegenerative or cognitive diseases. The method further provides for piperidine-2-one and piperidine-2-thione intermediates to compounds of formula (I).  
WO/2017/021881A1
Use of 2-(5S-Methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetamide or its pharmaceutically acceptable salt in manufacture of a medicament for prophylaxis and treatment of seizure.  

Matches 451 - 500 out of 123,566